Syndax Pharmaceuticals Inc SNDX
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Syndax Pharmaceuticals Inc (SNDX) is a healthcare company listed in the US with a market value of about $850M. In the twelve months to September 30, 2026 it had revenue of $290M and net income of -$209M, a net margin of -72.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 158% a year, a 5-year average ROIC of -27%.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $627000 in 2015 to $172M in 2025, growth of about 75.4% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 43% over three years (dilution for shareholders). It spends 150% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $290M | $172M | $24M | $0 | $0 | $140M | $2M | $2M | $2M | $2M | $1M |
| Net income | -$209M | -$285M | -$319M | -$209M | -$149M | $25M | -$73M | -$56M | -$74M | -$61M | -$44M |
| Free cash flow | -$177M | -$323M | -$275M | -$161M | -$134M | $29M | -$71M | — | -$69M | -$47M | -$35M |
| EPS (diluted) | $-2.36 | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 | $-1.87 | $-1.84 | $-2.92 | $-2.90 | $-3.22 |
| Net margin | -72.3% | -165.6% | -1346.1% | — | — | 17.8% | -4822.5% | -3694.6% | -4875.5% | -2884.3% | -3645.2% |
| ROIC | — | -51.8% | -28.0% | -32.7% | -25.6% | 4.8% | -20.7% | -139.9% | -110.3% | -46.9% | -41.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $35.45, 275% above the current price; targets range from $17.00 to $57.00; the consensus rating is “Strong buy”; expected EPS is $-2.13 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Syndax Pharmaceuticals pay a dividend?
Not currently.
Is Syndax Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Syndax Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.